Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.40 |
| ▸ | TAOK1 | Q7L7X3 | 4/20 | 0.40 |
| ▸ | HIPK4 | Q8NE63 | 4/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.40 |
| ▸ | PLK4 | O00444 | 3/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.40 |
| ▸ | MET | P08581 | 3/20 | 0.40 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.40 |
| ▸ | FLT4 | P35916 | 3/20 | 0.40 |
| ▸ | FLT3 | P36888 | 3/20 | 0.40 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.40 |
| ▸ | LCK | P06239 | 3/20 | 0.40 |
| ▸ | RET | P07949 | 3/20 | 0.40 |
| ▸ | BLK | P51451 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16154660 | 0.86 | KDR (0.36) | KDRROCK1CLK4ROCK2RPS6KB1 | |
| SCHEMBL16135661 | 0.78 | CLK4 (0.44) | KDRROCK1CLK4NTRK1MET | |
| SCHEMBL15984818 | 0.76 | ROCK1 (0.49) | KDRROCK1CLK4ROCK2RPS6KB1 | |
| SCHEMBL16135658 | 0.73 | MGLL (0.34) | FLT4PARP1 | |
| SCHEMBL16006664 | 0.73 | PARP1 (0.45) | CLK4TAOK1METFLT4ALK | |
| SCHEMBL16133544 | 0.73 | — | — | |
| SCHEMBL15980666 | 0.72 | ROCK1 (0.44) | KDRROCK1CLK4ROCK2RPS6KB1 | |
| SCHEMBL30190467 | 0.70 | CLK4 (0.51) | KDRROCK1CLK4ROCK2RPS6KB1 | |
| SCHEMBL20430124 | 0.69 | MAP3K14 (0.33) | FLT4 | |
| SCHEMBL16135649 | 0.67 | PIM1 (0.31) | FLT4PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3954679-A2 | AMIDE COMPOUNDS FOR THE TREATMENT OF HIV INFECTIONS | Gilead Sciences, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3409667-B1 | AMIDE COMPOUNDS FOR THE TREATMENT OF HIV INFECTIONS | GILEAD SCIENCES INC (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-2961742-B1 | AMIDE COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2018-08-01 | — | — | EP | disclosed |
| US-20160108030-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-04-21 | — | — | US | disclosed |
| US-20140303164-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2014-10-09 | — | — | US | disclosed |
| US-20140296266-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296266-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | KDR 3418/4885ROCK1 2390/4885CLK4 4766/4885 |
| US-20160108030-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, RPL35 | KDR 3469/4885ROCK1 2291/4885CLK4 4768/4885 |
| US-20140303164-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | KDR 3418/4885ROCK1 2390/4885CLK4 4766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.